A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies

BACKGROUND: Epidermal growth factor receptor (EGFR) is a well-known target for cancer treatment. However, the authorized anti-EGFR monoclonal antibodies generally cause several toxic effects, especially severe cutaneous toxicities as well as infusion reactions, and the clinical indications are limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Da, Pan, Hong, Wang, Wei, Xue, Yanan, Fang, Yong, Lou, Haizhou, Pan, Qin, Jin, Wei, Zheng, Yu, Han, Weidong, Zhu, Kongli, Zhao, Xianfeng, Xu, Rong, Han, Jin, Pan, Hongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071157/
https://www.ncbi.nlm.nih.gov/pubmed/37025261
http://dx.doi.org/10.1177/17588359231165968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071157/
https://www.ncbi.nlm.nih.gov/pubmed/37025261
http://dx.doi.org/10.1177/17588359231165968

Ejemplares similares